Skip to main content
OpenTrials
Completed

NCT Number: NCT05119647

A Single-Arm Objective Performance Criteria Trial for Intracranial Thrombus Aspiration Catheter

This is a prospective multicenter, single-arm objective performance criteria trial to assess the efficacy and safety of the the thrombus aspiration catheter.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The First Affiliated Hospital of USTC, Hefei, Anhui, China

Loading trial locations.

About this study

The study is conducted in 15 centers all around China, aiming at recruiting 155 patients with acute stroke caused by artery occlusion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years;
  • Baseline NIHSS score ≥6;
  • Subject has acute occlusion located in Vertebral artery(VA) / Internal Carotid Artery (ICA) / M1or M2 segment of Middle Cerebral Artery (MCA) / Basilar artery (BA) diagnosed by DSA;
  • Femoral artery puncture is expected to be completed within 24 hours of onset;
  • mRS score≤ 2;
  • Subject or legal representative is able to understand the purpose of study, agrees to comply with protocol requirements and has provided written informed consent.

Exclusion criteria

  • Chronic occlusion in the target area;
  • Epilepsy at the time of stroke;
  • Bleeding from the gastrointestinal or urinary system in the past three weeks;
  • After drug control, systolic blood pressure was greater than 185mmhg and / or diastolic blood pressure was greater than 110mmhg;
  • International Normalized Ratio(INR)>3;
  • Random blood glucose < 2.7mmol/L or > 22.2mmol/L;
  • Heart, lung, liver, kidney failure or other serious diseases (such as brain tumors, - systemic infection, active disseminated intravascular coagulation, myocardial infarction within 12 months before enrollment, history of severe mental illness);
  • Tortuous lesion / severe stenosis in the starting segment of the carotid artery / Carotid dissection / Arteritis judged by researchers that is not suitable for the procedure;
  • Acute occlusion of bilateral carotid arteries;
  • Intracranial hemorrhage or massive infarction diagnosed by CT or MR;
  • History of allergies to antiplatelet drugs, anticoagulants, anesthetics, contrast agents;
  • Expected life <12 months;
  • Female subjects who are pregnant or planning to become pregnant or lactate within the study period;
  • Subject has participated in any other drug or medical device clinical trials in 1 month before signing informed consent;
  • Other circumstances judged by researchers that are not suitable for enrollment .

Treatment and study plan

Thrombus Aspiration Catheter(Ton-bridgeMT)

Device

Thrombus Aspiration Catheter is a developed technique for treating acute stroke caused by artery occlusion. The catheter(Ton-bridgeMT) was specially designed for those patients who experience acute stroke within 24 hours.

Primary outcomes

  1. Successful recanalization rate within three-times aspiration

    Time frame: Up to 90 days

    Successful recanalization is defined as modified Thrombolysis In Cerebral Infarction scale(mTICI) 2b or 3 evaluated by Digital subtraction angiography (DSA).

Secondary outcomes

  1. Successful recanalization rate within three-times aspiration

    Time frame: Intraoperation

    Successful recanalization is defined as mTICI 2b or 3 evaluated by DSA.

  2. Successful recanalization rate beyond three-times aspiration

    Time frame: Intraoperation

    Successful recanalization is defined as mTICI 2b or 3 evaluated by DSA. Auxiliary device such as stent could be used.

  3. National Institute of Health stroke scale(NIHSS)

    Time frame: 72 hours / 7 days

    NIHSS score in 72 hours and 7 days(or the day when patients discharged, depends on which day is earlier) will be compared.

  4. Rate of Modified Rankin Scale(mRS) score less than 3

    Time frame: 90 days

    The mRS score is assessed in 90 days follow-up.

  5. Device delivery performance

    Time frame: Intraoperation

    Device delivery performance including transport and pullback performance, which is ranked excellent/good/normal/bad.

  6. The rate of symptomatic intracranial hemorrhage

    Time frame: 72 hours

    National Institute of Health stroke scale(NIHSS) increased by at least 4 compared with the baseline.

  7. Death rate

    Time frame: Up to 90 days

    Subjects who died from any cause would be counted.

  8. The rate of AE

    Time frame: Up to 90 days

    The definition of AE(Adverse Event) refers to ISO 14155

  9. The rate of SAE

    Time frame: Up to 90 days

    The definition of SAE (Serious Adverse Event) refers to ISO 14155

  10. The rate of medical device deficiency

    Time frame: Up to 90 days

    Medical device deficiency refer to the unreasonable risks of medical devices that may endanger human health and life safety under normal use in the process of clinical trials, such as label errors, quality problems, malfunctions, etc.

Sponsors and collaborators

Lead sponsor

Ton-Bridge Medical Tech. Co., Ltd

Industry

Registry information

Official study title

The Efficacy and Safety Study of Thrombus Aspiration Catheter(Ton-bridgeMT) on Endovascular Treatment of Acute Ischemic Stroke

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Nov 15, 2021
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.